Clinical Trial Update: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating adjuvant tumor lysate vaccine with Iscomatrix, with or without metronomic cyclophosphamide and celecoxib, in thoracic malignancies; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers of Non-thoracic Origin with Metastases to the Lungs or Pleura
• Thoracic Cancers
• Thoracic Sarcomas

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Celecoxib (Celecoxib)
• tumor lysate vaccine with Iscomatrix

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thoracic Sarcomas, Thorasic Cancers | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-01-26